Skip to main content

Table 1 Pathogenic and likely pathogenic classified variants identified in Long Life Family Study

From: Prevalence of clinically actionable disease variants in exceptionally long-lived families

SNP ID*GeneAmino Acid ChangeRandom LLFS Sampling FrequencyPopulation Frequencyp-valueACMG Variant Classification: Criteria*Number of LLFS Participants with Variant
rs28897686: NM_007294.3:c.3748G > TBRCA1p.Glu1250*2.57 × 10−47.90 × 10−61P: PVS1, PM2, PP53 heterozygotes
rs764575966: NM_003001.3:c.397C > TSDHCp.Arg133*7.71 × 10−43.20 × 10−50.05P: PVS1, PM2, PP53 heterozygotes
rs74315294: NM_000098.3:c.338C > TCPT2p.Ser113Leu3.96 × 10−31.38 × 10− 30.11P: PM1, PM2, PP3, PP5391 heterozygotes
3 homozygotes
rs121434280: NM_001127328.2:c.211 T > CACADMp.Tyr71His2.06 × 10−44.87 × 10− 41LP: PS3, PM2, PP5, BP4136 heterozygotes
rs201375579: NM_001127328.2:c.809A > GACADMp.Asp270Gly4.30 × 10−52.97 × 10−41LP: PS3, PM279 heterozygotes
rs138058572: NM_001270447.1:c.1427G > AACADVLp.Arg476Gln2.98 × 10−47.20 × 10−6N/ALP: PS4, PM2, PP31 heterozygote
rs28904921: NM_000051.3:c.7271 T > GATMp.Val2424Gly2.20 × 10−55.06 × 10− 51LP: PS3, PM2,PP3,PP514 heterozygotes
rs137852849: NM_001164675.1:c.836C > TSUMF1p.Ala279Val2.24 × 10−41.12 × 10− 41LP: PS3, PM2,PP531 heterozygotes
rs17847577: NM_000553.4:c.1105C > TWRNp.Arg369*1.73 × 10−41.88 × 10− 41P: PVS1, PM2, PP553 heterozygotes
  1. *P Pathogenic, LP Likely Pathogenic
  2. PVS1: nonsense (stop-gain) mutation where loss of function is a known mechanism of disease
  3. PM2: Low allele frequency in genomic databases
  4. PP5: Reputable source(s) classified variant as pathogenic
  5. PS3: Well-established in vitro or in vivo functional studies supportive of a damaging effect on the gene or gene product
  6. PM1: Located in a mutational hot spot and/or critical and well-established functional domain (e.g., active site of an enzyme) without benign variation
  7. PP3: Multiple lines of computational evidence support a deleterious effect on the gene or gene product (conservation, evolutionary, splicing impact, etc.)
  8. BP4: Multiple lines of computational evidence suggest no impact on gene or gene product (conservation, evolutionary, splicing impact, etc.)
  9. PS4: The prevalence of the variant in affected individuals is significantly increased compared with the prevalence in controls
  10. In-silico algorithms used for PP3 criterion:
  11. CPT2 NM_000098.3:c.338C > T: Pathogenic prediction from multiple computational programs (PhyloP: C; SIFT: D; PolyPhen-2: D; Likelihood Ratio Test (LRT): D; MutationTaster: D; GERP: D)
  12. ACADM NM_001127328.2:c.211 T > C: Benign prediction from multiple computational programs (PhyloP: C; SIFT: T; PolyPhen-2: B; Likelihood Ratio Test (LRT): N; MutationTaster: D; GERP: D)
  13. ACADVL NM_001270447.1:c.1427G > A: Pathogenic prediction from multiple computational programs (PhyloP: C; SIFT: D; PolyPhen-2: D; Likelihood Ratio Test (LRT): D; MutationTaster: D; GERP: D)
  14. ATM NM_000051.3:c.7271 T > G: Pathogenic prediction from multiple computational programs (PhyloP: C; SIFT: D; PolyPhen-2: D; Likelihood Ratio Test (LRT): D; MutationTaster: N; GERP: D)
  15. PhyloP: Conserved (C) or not conserved (N); SIFT: Deleterious (D) or tolerated (T); PolyPhen-2: Damaging (D), possibly damaging (P), or benign (B); Likelihood Ratio Test (LRT): Deleterious (D) or neutral (N); MutationTaster: Deleterious (D) or neutral (N); GERP: Deleterious (D) or neutral (N)